<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559529</url>
  </required_header>
  <id_info>
    <org_study_id>VEPP_200915</org_study_id>
    <nct_id>NCT04559529</nct_id>
  </id_info>
  <brief_title>Pharmacological Modulation of Hippocampal Activity in Psychosis 2</brief_title>
  <official_title>Pharmacological Modulation of Hippocampal Activity in Psychosis 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether administration of levetiracetam (LEV), a&#xD;
      commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal&#xD;
      hyperactivity in people with psychotic disorders. Specifically, the investigators will&#xD;
      utilize two functional magnetic resonance imaging (MRI) techniques: 1)&#xD;
      blood-oxygen-level-dependent (BOLD) contrast will assess activity with a visual scene&#xD;
      processing task that engages the anterior hippocampus and 2) arterial spin labeling (ASL)&#xD;
      will assess baseline activity. Previous studies in people with psychotic disorders have shown&#xD;
      that the hippocampus is hyperactive and more activity correlates with worsening of clinical&#xD;
      symptoms. Therefore, the aim of this study is to use an intervention to further understand&#xD;
      the underlying mechanisms of the hippocampus in psychosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">September 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2-way crossover, double-blind, randomized controlled study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>During Visit 2, participants will be randomly assigned to an intervention arm in which they will receive two 250mg LEV capsules or two placebo capsules. Both the participant and the research team will be blinded to which arm each participant is in. During Visit 3, the participant will undergo cross-over and receive either two 250mg LEV capsules or two placebo capsules (whichever intervention they did not receive in Visit 2).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hippocampal activity (Arterial Spin Labeling [ASL] study)</measure>
    <time_frame>2 hours after administration</time_frame>
    <description>Change in ASL signal after intervention, using Magnetic Resonance Imaging (MRI) scanning of the brain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal recruitment (Blood-Oxygen-Level-Dependent [BOLD] study)</measure>
    <time_frame>2 hours after administration</time_frame>
    <description>Change in BOLD signal after intervention, using Magnetic Resonance Imaging (MRI) scanning of the brain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia; Psychosis</condition>
  <arm_group>
    <arm_group_label>Levetiracetam (LEV), then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will first receive two 250mg LEV capsules on the same day. After one week, they will receive two placebo capsules on the same day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then Levetiracetam (LEV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will first receive two placebo capsules on the same day. After one week, they will receive two 250mg LEV capsules on the same day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam (LEV) 500 mg</intervention_name>
    <description>The levetiracetam pill will look just like the placebo pill.</description>
    <arm_group_label>Levetiracetam (LEV), then Placebo</arm_group_label>
    <arm_group_label>Placebo, then Levetiracetam (LEV)</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo pill will look just like the levetiracetam pill, but does not contain any levetiracetam.</description>
    <arm_group_label>Levetiracetam (LEV), then Placebo</arm_group_label>
    <arm_group_label>Placebo, then Levetiracetam (LEV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for psychosis subjects&#xD;
&#xD;
          1. Men and women age 18 - 65.&#xD;
&#xD;
          2. Communicative in English.&#xD;
&#xD;
          3. Provide voluntary, written informed consent.&#xD;
&#xD;
          4. Physically healthy by medical history.&#xD;
&#xD;
          5. BMI &gt; 17.5 and &lt; 45.&#xD;
&#xD;
          6. Diagnosis of a psychotic disorder confirmed by Structured Clinical Interview for&#xD;
             Diagnostic and Statistical Manual-5 (SCID) or diagnostic interview with a trained&#xD;
             clinician.&#xD;
&#xD;
          7. Stable medication regimen over at least the past two weeks, including the use of&#xD;
             either an oral or intramuscular administration of an antipsychotic medication.&#xD;
&#xD;
          8. For females, no longer of child-bearing potential, or agreeing to practice effective&#xD;
             contraception during the study (e.g., established use of oral, injected or implanted&#xD;
             hormonal methods of contraception; placement of an intrauterine device or intrauterine&#xD;
             system; barrier methods: condom with spermicidal foam/gel/film/cream/suppository or&#xD;
             occlusive cap [diaphragm or cervical/vault caps] with spermicidal&#xD;
             foam/gel/film/cream/suppository; male partner sterilization; or true abstinence when&#xD;
             this is in line with the preferred and usual lifestyle of the subject); and,&#xD;
&#xD;
          9. For females of child-bearing potential, must have a negative urine pregnancy test&#xD;
             before MRI and drug administration.&#xD;
&#xD;
         10. Not breastfeeding/nursing at time of screening or at any time during the study.&#xD;
&#xD;
        Inclusion criteria for healthy controls&#xD;
&#xD;
        1. All of the above except for subjects will be psychiatrically healthy and not taking&#xD;
        psychotropic or potentially psychoactive prescription medication.&#xD;
&#xD;
        ----&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria for psychosis subjects&#xD;
&#xD;
          1. Age less than 18 or greater than 65.&#xD;
&#xD;
          2. Not communicative in English.&#xD;
&#xD;
          3. Unable to provide written informed consent.&#xD;
&#xD;
          4. Current medical or neurological illness.&#xD;
&#xD;
          5. History of severe head trauma.&#xD;
&#xD;
          6. BMI &lt; 17.5 or &gt; 45.&#xD;
&#xD;
          7. Meets criteria for diagnosis of substance or alcohol use disorder within the past&#xD;
             month.&#xD;
&#xD;
          8. Positive urine pregnancy test during the study.&#xD;
&#xD;
          9. Breastfeeding/nursing at time of screening or at any time during the study.&#xD;
&#xD;
         10. Conditions that preclude MR scanning (as defined in the Screening Form)&#xD;
&#xD;
         11. Conditions that preclude study drug administration (as defined in the Screening Form)&#xD;
&#xD;
        Exclusion criteria for healthy controls&#xD;
&#xD;
        All of the above and in addition:&#xD;
&#xD;
          1. Current use of psychotropic or potentially psychoactive prescription medication.&#xD;
&#xD;
          2. Major psychiatric disorder as determined by Diagnostic and Statistical Manual -5&#xD;
             (major depression, bipolar disorder, obsessive compulsive disorder, post-traumatic&#xD;
             stress disorder, etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Heckers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Stephan Heckers</investigator_full_name>
    <investigator_title>Dept Chairperson Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

